These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20822342)

  • 1. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.
    Vaccari M; Poonam P; Franchini G
    Expert Rev Vaccines; 2010 Sep; 9(9):997-1005. PubMed ID: 20822342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 prophylactic vaccine trials in Thailand.
    Pitisuttithum P
    Curr HIV Res; 2005 Jan; 3(1):17-30. PubMed ID: 15638720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
    Montefiori DC; Karnasuta C; Huang Y; Ahmed H; Gilbert P; de Souza MS; McLinden R; Tovanabutra S; Laurence-Chenine A; Sanders-Buell E; Moody MA; Bonsignori M; Ochsenbauer C; Kappes J; Tang H; Greene K; Gao H; LaBranche CC; Andrews C; Polonis VR; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Self SG; Berman PW; Francis D; Sinangil F; Lee C; Tartaglia J; Robb ML; Haynes BF; Michael NL; Kim JH
    J Infect Dis; 2012 Aug; 206(3):431-41. PubMed ID: 22634875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
    Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
    Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus vaccine trials.
    O'Connell RJ; Kim JH; Corey L; Michael NL
    Cold Spring Harb Perspect Med; 2012 Dec; 2(12):a007351. PubMed ID: 23209178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonreplicating vectors in HIV vaccines.
    Johnson JA; Barouch DH; Baden LR
    Curr Opin HIV AIDS; 2013 Sep; 8(5):412-20. PubMed ID: 23925001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
    Pitisuttithum P; Rerks-Ngarm S; Bussaratid V; Dhitavat J; Maekanantawat W; Pungpak S; Suntharasamai P; Vanijanonta S; Nitayapan S; Kaewkungwal J; Benenson M; Morgan P; O'Connell RJ; Berenberg J; Gurunathan S; Francis DP; Paris R; Chiu J; Stablein D; Michael NL; Excler JL; Robb ML; Kim JH
    PLoS One; 2011; 6(12):e27837. PubMed ID: 22205930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
    Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Chiu J; Paris R; Premsri N; Namwat C; de Souza M; Adams E; Benenson M; Gurunathan S; Tartaglia J; McNeil JG; Francis DP; Stablein D; Birx DL; Chunsuttiwat S; Khamboonruang C; Thongcharoen P; Robb ML; Michael NL; Kunasol P; Kim JH;
    N Engl J Med; 2009 Dec; 361(23):2209-20. PubMed ID: 19843557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RV144: old vs. new.
    Weiner DB
    Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
    Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
    Front Immunol; 2020; 11():719. PubMed ID: 32411138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for eliciting HIV-1 inhibitory antibodies.
    Tomaras GD; Haynes BF
    Curr Opin HIV AIDS; 2010 Sep; 5(5):421-7. PubMed ID: 20978384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
    Gray GE; Bekker LG; Laher F; Malahleha M; Allen M; Moodie Z; Grunenberg N; Huang Y; Grove D; Prigmore B; Kee JJ; Benkeser D; Hural J; Innes C; Lazarus E; Meintjes G; Naicker N; Kalonji D; Nchabeleng M; Sebe M; Singh N; Kotze P; Kassim S; Dubula T; Naicker V; Brumskine W; Ncayiya CN; Ward AM; Garrett N; Kistnasami G; Gaffoor Z; Selepe P; Makhoba PB; Mathebula MP; Mda P; Adonis T; Mapetla KS; Modibedi B; Philip T; Kobane G; Bentley C; Ramirez S; Takuva S; Jones M; Sikhosana M; Atujuna M; Andrasik M; Hejazi NS; Puren A; Wiesner L; Phogat S; Diaz Granados C; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; McElrath MJ; Gilbert PB; Janes H; Corey L;
    N Engl J Med; 2021 Mar; 384(12):1089-1100. PubMed ID: 33761206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 19. Support for the RV144 HIV vaccine trial.
    AIDS Vaccine Advocacy Coalition
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15250069
    [No Abstract]   [Full Text] [Related]  

  • 20. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
    Kim JH; Excler JL; Michael NL
    Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.